IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-39139-4.html
   My bibliography  Save this article

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

Author

Listed:
  • Shen Zhao

    (Sun Yat-sen University Cancer Center)

  • Wu Zhuang

    (Fujian Cancer Hospital)

  • Baohui Han

    (Shanghai Chest Hospital)

  • Zhengbo Song

    (Zhejiang Cancer Hospital)

  • Wei Guo

    (Shanxi Provincial Cancer Hospital)

  • Feng Luo

    (Sichuan University)

  • Lin Wu

    (Hunan Cancer Hospital)

  • Yi Hu

    (Chinese PLA General Hospital)

  • Huijuan Wang

    (Henan Cancer Hospital)

  • Xiaorong Dong

    (Huazhong University of Science and Technology)

  • Da Jiang

    (The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital)

  • Mingxia Wang

    (The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital)

  • Liyun Miao

    (the Affiliated Hospital of Nanjing University Medical School)

  • Qian Wang

    (Jiangsu Province Hospital of Chinese Medicine)

  • Junping Zhang

    (Shanxi Bethune Hospital)

  • Zhenming Fu

    (Renmin Hospital of Wuhan University)

  • Yihua Huang

    (Sun Yat-sen University Cancer Center)

  • Chunwei Xu

    (Nanjing University School of Medicine)

  • Longyu Hu

    (HaploX Biotechnology Co,. Ltd.)

  • Lei Li

    (CSPC Pharmaceutical Group Co., Ltd)

  • Rong Hu

    (CSPC Pharmaceutical Group Co., Ltd)

  • Yang Yang

    (CSPC Pharmaceutical Group Co., Ltd)

  • Mengke Li

    (CSPC Pharmaceutical Group Co., Ltd)

  • Xiugao Yang

    (CSPC Pharmaceutical Group Co., Ltd)

  • Li Zhang

    (Sun Yat-sen University Cancer Center)

  • Yan Huang

    (Sun Yat-sen University Cancer Center)

  • Wenfeng Fang

    (Sun Yat-sen University Cancer Center)

Abstract

EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerability, potential mechanisms of response and resistance for dual targeting EGFR 20ins with JMT101 (anti-EGFR monoclonal antibody) plus osimertinib from preclinical models and an open label, multi-center phase 1b trial (NCT04448379). Primary endpoint of the trial is tolerability. Secondary endpoints include objective response rate, duration of response, disease control rate, progression free survival, overall survival, the pharmacokinetic profile of JMT101, occurrence of anti-drug antibodies and correlation between biomarkers and clinical outcomes. A total of 121 patients are enrolled to receive JMT101 plus osimertinib 160 mg. The most common adverse events are rash (76.9%) and diarrhea (63.6%). The confirmed objective response rate is 36.4%. Median progression-free survival is 8.2 months. Median duration of response is unreached. Subgroup analyses were performed by clinicopathological features and prior treatments. In patients with platinum-refractory diseases (n = 53), confirmed objective response rate is 34.0%, median progression-free survival is 9.2 months and median duration of response is 13.3 months. Responses are observed in distinct 20ins variants and intracranial lesions. Intracranial disease control rate is 87.5%. Confirmed intracranial objective response rate is 25%.

Suggested Citation

  • Shen Zhao & Wu Zhuang & Baohui Han & Zhengbo Song & Wei Guo & Feng Luo & Lin Wu & Yi Hu & Huijuan Wang & Xiaorong Dong & Da Jiang & Mingxia Wang & Liyun Miao & Qian Wang & Junping Zhang & Zhenming Fu , 2023. "Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
  • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39139-4
    DOI: 10.1038/s41467-023-39139-4
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-39139-4
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-023-39139-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Yong Jia & Cai-Hong Yun & Eunyoung Park & Dalia Ercan & Mari Manuia & Jose Juarez & Chunxiao Xu & Kevin Rhee & Ting Chen & Haikuo Zhang & Sangeetha Palakurthi & Jaebong Jang & Gerald Lelais & Michael , 2016. "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors," Nature, Nature, vol. 534(7605), pages 129-132, June.
    2. Jacqulyne P. Robichaux & Xiuning Le & R. S. K. Vijayan & J. Kevin Hicks & Simon Heeke & Yasir Y. Elamin & Heather Y. Lin & Hibiki Udagawa & Ferdinandos Skoulidis & Hai Tran & Susan Varghese & Junqin H, 2021. "Structure-based classification predicts drug response in EGFR-mutant NSCLC," Nature, Nature, vol. 597(7878), pages 732-737, September.
    3. Paula D. Bos & Xiang H.-F. Zhang & Cristina Nadal & Weiping Shu & Roger R. Gomis & Don X. Nguyen & Andy J. Minn & Marc J. van de Vijver & William L. Gerald & John A. Foekens & Joan Massagué, 2009. "Genes that mediate breast cancer metastasis to the brain," Nature, Nature, vol. 459(7249), pages 1005-1009, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bieke Decaesteker & Amber Louwagie & Siebe Loontiens & Fanny De Vloed & Sarah-Lee Bekaert & Juliette Roels & Suzanne Vanhauwaert & Sara De Brouwer & Ellen Sanders & Alla Berezovskaya & Geertrui Deneck, 2023. "SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    2. Weili Ma & Maria Cecília Oliveira-Nunes & Ke Xu & Andrew Kossenkov & Benjamin C. Reiner & Richard C. Crist & James Hayden & Qing Chen, 2023. "Type I interferon response in astrocytes promotes brain metastasis by enhancing monocytic myeloid cell recruitment," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    3. Jenniffer Linares & Anna Sallent-Aragay & Jordi Badia-Ramentol & Alba Recort-Bascuas & Ana Méndez & Noemí Manero-Rupérez & Daniele Lo Re & Elisa I. Rivas & Marc Guiu & Melissa Zwick & Mar Iglesias & C, 2023. "Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    4. R. Sumanth Iyer & Sarah R. Needham & Ioannis Galdadas & Benjamin M. Davis & Selene K. Roberts & Rico C. H. Man & Laura C. Zanetti-Domingues & David T. Clarke & Gilbert O. Fruhwirth & Peter J. Parker &, 2024. "Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers," Nature Communications, Nature, vol. 15(1), pages 1-21, December.
    5. Tikvah K. Hayes & Elisa Aquilanti & Nicole S. Persky & Xiaoping Yang & Erica E. Kim & Lisa Brenan & Amy B. Goodale & Douglas Alan & Ted Sharpe & Robert E. Shue & Lindsay Westlake & Lior Golomb & Brian, 2024. "Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    6. Lingzhi Hong & Muhammad Aminu & Shenduo Li & Xuetao Lu & Milena Petranovic & Maliazurina B. Saad & Pingjun Chen & Kang Qin & Susan Varghese & Waree Rinsurongkawong & Vadeerat Rinsurongkawong & Amy Spe, 2023. "Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    7. Wonbin Park & Jae-Seong Lee & Ge Gao & Byoung Soo Kim & Dong-Woo Cho, 2023. "3D bioprinted multilayered cerebrovascular conduits to study cancer extravasation mechanism related with vascular geometry," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    8. Sunny Li-Yun Chang & Po-Jen Yang & Yen-You Lin & Ya-Jing Jiang & Po-I Liu & Chang-Lun Huang & Shun-Fa Yang & Chih-Hsin Tang, 2022. "Genetic Associations of Visfatin Polymorphisms with EGFR Status and Clinicopathologic Characteristics in Lung Adenocarcinoma," IJERPH, MDPI, vol. 19(22), pages 1-11, November.
    9. Iris K. Alderwerelt van Rosenburgh & David M. Lu & Michael J. Grant & Steven E. Stayrook & Manali Phadke & Zenta Walther & Sarah B. Goldberg & Katerina Politi & Mark A. Lemmon & Kumar D. Ashtekar & Yu, 2022. "Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    10. Hui Deng & Qian Lei & Chengdi Wang & Zhoufeng Wang & Hai Chen & Gang Wang & Na Yang & Dan Huang & Quanwei Yu & Mengling Yao & Xue Xiao & Guonian Zhu & Cheng Cheng & Yangqian Li & Feng Li & Panwen Tian, 2022. "A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    11. Mengmeng Niu & Jing Xu & Yang Liu & Yuhuang Li & Tao He & Liangping Ding & Yajun He & Yong Yi & Fengtian Li & Rongtian Guo & Ya Gao & Rui Li & Luping Li & Mengyuan Fu & Qingyong Hu & Yangkun Luo & Chu, 2021. "FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    12. Nicola Cosgrove & Damir Varešlija & Stephen Keelan & Ashuvinee Elangovan & Jennifer M. Atkinson & Sinéad Cocchiglia & Fiona T. Bane & Vikrant Singh & Simon Furney & Chunling Hu & Jodi M. Carter & Stev, 2022. "Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    13. Erik B. Faber & Luxin Sun & Jian Tang & Emily Roberts & Sornakala Ganeshkumar & Nan Wang & Damien Rasmussen & Abir Majumdar & Laura E. Hirsch & Kristen John & An Yang & Hira Khalid & Jon E. Hawkinson , 2023. "Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    14. Ke Li & Jiawei Guo & Yue Ming & Shuang Chen & Tingting Zhang & Hulin Ma & Xin Fu & Jin Wang & Wenrong Liu & Yong Peng, 2023. "A circular RNA activated by TGFβ promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    15. Xiajing Gong & Meng Hu & Jinzhong Liu & Geoffrey Kim & James Xu & Amy McKee & Todd Palmby & R. Angelo Claro & Liang Zhao, 2022. "Decoding kinase-adverse event associations for small molecule kinase inhibitors," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    16. Tyler S. Beyett & Ciric To & David E. Heppner & Jaimin K. Rana & Anna M. Schmoker & Jaebong Jang & Dries J. H. Clercq & Gabriel Gomez & David A. Scott & Nathanael S. Gray & Pasi A. Jänne & Michael J. , 2022. "Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    17. Bo Jiang & Xiaozhi Zhao & Wei Chen & Wenli Diao & Meng Ding & Haixiang Qin & Binghua Li & Wenmin Cao & Wei Chen & Yao Fu & Kuiqiang He & Jie Gao & Mengxia Chen & Tingsheng Lin & Yongming Deng & Chao Y, 2022. "Lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating BMPR1A lysosomal degradation," Nature Communications, Nature, vol. 13(1), pages 1-17, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39139-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.